Bharat Biotech gets CDSCO nod for shelf-life extension of Covaxin
Advertisement
Bengaluru: Bharat Biotech's COVID-19 vaccine has been granted an extension of shelf life for up to 12 months from the date of manufacture by India's drug regulator, Central Drugs Standard Control Organisation (CDSCO) the company said on Wednesday.
Covaxin initially had a shelf life of six months when it first received emergency use approval in the country, which was later extended to nine months, a company spokeswoman told Reuters.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.